Acino International AG

Switzerland · owned by Arcera (United Arab Emirates) · acino.swiss · 32 vendors

Acino International AG is a Swiss pharmaceutical company headquartered in Zurich that develops, manufactures, and markets medicines with a clear focus on emerging markets in Africa, Latin America, the Middle East, Türkiye, Ukraine, and Eurasian countries. The company has over 50 years of experience producing oral solid dose (OSD) products and offers contract manufacturing and out-licensing services to leading global pharma companies. Acino is part of Arcera, a global life sciences company headquartered in Abu Dhabi, UAE, established by ADQ, an Abu Dhabi-based investment and holding company.

Resilience scores

Technology vendors

Insights

Last updated 2026-04-29 · revision 51

32 direct vendors, 299 subvendors

Direct vendors by controlling owner country (sample)

Subvendors by controlling owner country (sample)

Migration Readiness: 5/10

Assessed by AI based on technology stack characteristics (cloud-native vs legacy, containerization, microservices), regulatory environment, data residency requirements, financial stability, and vendor lock-in risks. The score ranges from 0-10, where higher scores indicate better readiness for technology migration.

Reasoning: Acino is a well-established pharmaceutical company with a global presence. While specific details of its internal tech stack are not publicly available, companies in this sector typically have a mix of legacy systems (e.g., ERP, LIMS, QMS) and more modern solutions. The pharmaceutical industry often relies on validated systems, which can make rapid migration challenging due to stringent regulatory requirements and validation processes. However, a global company of Acino's size would likely have adopted some level of cloud services for non-critical applications or data analytics. The score of 5 reflects a balanced view, assuming a moderate level of cloud adoption and some flexibility, but also acknowledging the inherent complexities and potential vendor lock-in associated with specialized pharmaceutical software and validated systems. Confidence: Medium (inference based on industry standards and company profile).

Financials

Three-year financials

Financial Resilience Score: null/10

Acino's acquisition by ADQ is the single most significant factor underpinning its financial resilience. ADQ is one of the region's largest holding companies with a vast portfolio and deep capital reserves. This ownership structure provides Acino with exceptional access to long-term, strategic capital for growth, acquisitions, and navigating economic downturns, insulating it from the financing pressures faced by independent or publicly-listed peers. The pharmaceutical sector is inherently defensive. Demand for essential medicines is largely inelastic and not closely tied to economic cycles, providing a stable revenue base. Acino's focus on emerging markets across the Middle East, Africa, CIS, and Latin America diversifies its revenue streams. While these markets carry higher political and currency risks, they also offer superior growth rates compared to the saturated markets of North America and Western Europe. This diversification mitigates the impact of a downturn in any single region. The company has a successful track record of acquiring and integrating assets, most notably the portfolio from Takeda in 2017. This demonstrates operational strength and an ability to generate value from strategic investments, which enhances long-term financial health.

Key strengths: Sovereign Wealth Fund Ownership, Recession-Resistant Industry, Geographic Diversification, Proven M&A Integration Capability

Risk factors: Emerging Market Volatility, Integration Risk

Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.

View the full interactive report